[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:endometrial-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":350},"Endometrial Carcinoma",224,199,[8,16,22,29,35,42,49,55,61,67,73,79,85,92,98,105,111,117,123,129,135,141,147,153,159,165,171,177,183,190,196,202,208,214,220,226,232,238,243,249,255,261,266,272,278,284,290,295,300,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07209449","A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer",[12],"Phase 2","RECRUITING","2026-08-26T02:16:06.684983Z","2026-07-19T19:36:05.071435Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07270666","ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer",[],"2026-08-26T02:16:20.336282Z","2026-07-19T19:36:05.068430Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05691010","A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer",[26],"Early Phase 1","2026-08-26T02:16:02.918558Z","2026-07-05T05:32:16.812261Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT03675893","RESOLVE: Abemaciclib + Letrozole +\u002F- Metformin or Gedatolisib in Endometrial Cancer",[12],"2026-08-26T02:16:36.513735Z","2026-07-05T05:32:16.773482Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT07166094","Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer",[39],"Phase 3","2026-08-26T02:16:58.658552Z","2026-07-05T05:32:16.735284Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT07318324","Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer",[46],"Phase 1","2026-08-26T02:17:46.653867Z","2026-07-05T05:32:16.676290Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT07594015","Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy",[12],"2026-08-26T02:18:33.598205Z","2026-05-29T15:36:40.203701Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07022483","Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+\u002F2+) Endometrial Cancer",[39],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.698094Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT03832361","Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer",[12],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:29.680225Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06677112","MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer",[],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:29.645346Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07065552","Tirzepatide in Obesity-Driven Endometrial Cancer",[26],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:29.542809Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06518564","Avelumab and M1774 in ARID1A-mutated Endometrial Cancer",[12],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:29.528641Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":90,"content_modified":91},"NCT04683653","Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer",[89],"Phase 1\u002FPhase 2","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:29.483567Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT06952504","A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033\u002FTroFuse-033\u002FGOG-3119\u002FENGOT-en29)",[39],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.464456Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":103,"content_modified":104},"NCT07513493","Pipelle vs the Curved Aspirator Device",[102],"Phase 4","2026-08-26T02:15:17.167444Z","2026-05-05T02:43:29.402060Z",{"nct_id":106,"title":107,"phases":108,"status":13,"updated_at":109,"content_modified":110},"NCT05758688","PROton Therapy for Post Surgical Treatment of GYNecologic Cancer",[12],"2026-08-26T02:17:03.534765Z","2026-05-05T02:43:29.388258Z",{"nct_id":112,"title":113,"phases":114,"status":13,"updated_at":115,"content_modified":116},"NCT05542407","ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer",[46],"2026-08-26T02:15:50.539717Z","2026-05-05T02:43:28.973834Z",{"nct_id":118,"title":119,"phases":120,"status":13,"updated_at":121,"content_modified":122},"NCT06366347","ALPINE: Maintenance Letrozole\u002FAbemaciclib",[12],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:28.884662Z",{"nct_id":124,"title":125,"phases":126,"status":13,"updated_at":127,"content_modified":128},"NCT04469764","Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer",[12],"2026-08-26T02:15:14.574786Z","2026-05-05T02:43:28.703321Z",{"nct_id":130,"title":131,"phases":132,"status":13,"updated_at":133,"content_modified":134},"NCT05903131","Uterine Preservation Via Lifestyle Transformation",[12],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:28.674886Z",{"nct_id":136,"title":137,"phases":138,"status":13,"updated_at":139,"content_modified":140},"NCT06925724","A Study of Ivonescimab in People With Endometrial and Cervical Cancers",[12],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:28.562258Z",{"nct_id":142,"title":143,"phases":144,"status":13,"updated_at":145,"content_modified":146},"NCT07415681","GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries",[12],"2026-08-26T02:17:54.420226Z","2026-05-05T02:43:28.558894Z",{"nct_id":148,"title":149,"phases":150,"status":13,"updated_at":151,"content_modified":152},"NCT05640999","Adjuvant Therapy in POLE-Mutated and p53-Wildtype\u002FNSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER",[12],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:28.517766Z",{"nct_id":154,"title":155,"phases":156,"status":13,"updated_at":157,"content_modified":158},"NCT06989112","DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+\u002F2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer",[39],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:28.516336Z",{"nct_id":160,"title":161,"phases":162,"status":13,"updated_at":163,"content_modified":164},"NCT06253494","Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer",[89],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.474793Z",{"nct_id":166,"title":167,"phases":168,"status":13,"updated_at":169,"content_modified":170},"NCT04774419","Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery",[12],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.401063Z",{"nct_id":172,"title":173,"phases":174,"status":13,"updated_at":175,"content_modified":176},"NCT06384807","A Phase 1\u002F2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors",[89],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.366617Z",{"nct_id":178,"title":179,"phases":180,"status":13,"updated_at":181,"content_modified":182},"NCT04567771","Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer",[],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:28.348364Z",{"nct_id":184,"title":185,"phases":186,"status":13,"updated_at":188,"content_modified":189},"NCT05797831","Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer",[187],"Phase 2\u002FPhase 3","2026-08-26T02:18:25.327036Z","2026-05-05T02:43:28.334159Z",{"nct_id":191,"title":192,"phases":193,"status":13,"updated_at":194,"content_modified":195},"NCT07198074","Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer",[39],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:28.219924Z",{"nct_id":197,"title":198,"phases":199,"status":13,"updated_at":200,"content_modified":201},"NCT04586959","Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer",[],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:28.127186Z",{"nct_id":203,"title":204,"phases":205,"status":13,"updated_at":206,"content_modified":207},"NCT05819892","Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer",[46],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:28.021928Z",{"nct_id":209,"title":210,"phases":211,"status":13,"updated_at":212,"content_modified":213},"NCT06040970","Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer",[89],"2026-08-26T02:16:00.194860Z","2026-05-05T02:43:27.837801Z",{"nct_id":215,"title":216,"phases":217,"status":13,"updated_at":218,"content_modified":219},"NCT05950464","Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer",[46],"2026-08-26T02:17:27.435233Z","2026-05-05T02:43:27.816353Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT06538337","Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers",[],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.812635Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT05603910","Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent\u002FUnresectable Endometrial Carcinoma",[46],"2026-08-26T02:18:38.077159Z","2026-05-05T02:43:27.804429Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT06340568","A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer",[39],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:27.635834Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":163,"content_modified":242},"NCT07044336","Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)",[39],"2026-05-05T02:43:27.571764Z",{"nct_id":244,"title":245,"phases":246,"status":13,"updated_at":247,"content_modified":248},"NCT06746428","Activity Coaching During Pelvic Radiation Therapy",[],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:27.435583Z",{"nct_id":250,"title":251,"phases":252,"status":13,"updated_at":253,"content_modified":254},"NCT04486352","A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer",[89],"2026-08-26T02:15:01.639696Z","2026-05-05T02:43:27.406207Z",{"nct_id":256,"title":257,"phases":258,"status":13,"updated_at":259,"content_modified":260},"NCT03785288","Vaginal Cuff Brachytherapy Fractionation Study",[39],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:26.921405Z",{"nct_id":262,"title":263,"phases":264,"status":13,"updated_at":33,"content_modified":265},"NCT06481592","A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.",[12],"2026-05-05T02:43:26.671273Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":270,"content_modified":271},"NCT04073706","Sentinel Node Biopsy in Endometrial Cancer",[39],"2026-08-26T02:18:47.742071Z","2026-04-29T02:57:57.126240Z",{"nct_id":273,"title":274,"phases":275,"status":13,"updated_at":276,"content_modified":277},"NCT04165772","Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors",[12],"2026-08-26T02:19:11.399072Z","2026-07-05T05:32:16.775552Z",{"nct_id":279,"title":280,"phases":281,"status":13,"updated_at":282,"content_modified":283},"NCT07419841","A Phase 1 Study of the Safety and Tolerability of CTX-10726",[46],"2026-08-26T02:18:55.570428Z","2026-07-05T05:32:16.684256Z",{"nct_id":285,"title":286,"phases":287,"status":13,"updated_at":288,"content_modified":289},"NCT06167317","Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors",[46],"2026-08-26T02:16:31.714843Z","2026-06-17T19:21:16.603297Z",{"nct_id":291,"title":292,"phases":293,"status":13,"updated_at":40,"content_modified":294},"NCT03686124","ACTengine® IMA203\u002FIMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and\u002For Refractory Solid Tumors",[89],"2026-05-05T02:43:29.324355Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":151,"content_modified":299},"NCT07139977","Study of EV for Recurrent Endometrial Carcinoma",[12],"2026-05-05T02:43:29.320525Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":133,"content_modified":304},"NCT07383506","A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors",[46],"2026-05-05T02:43:29.192289Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT07306559","A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)",[46],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:29.158628Z",[312,316,320,323,327,331,334,338,341,344,347],{"biomarker":313,"count":314,"slug":315},"MRC1 wt Allele",21,"mrc1-wt-allele",{"biomarker":317,"count":318,"slug":319},"ERBB2 Gene",12,"erbb2-gene",{"biomarker":321,"count":318,"slug":322},"MSI1 Gene","msi1-gene",{"biomarker":324,"count":325,"slug":326},"TP53 Gene",5,"tp53-gene",{"biomarker":328,"count":329,"slug":330},"BRAF Gene",4,"braf-gene",{"biomarker":332,"count":329,"slug":333},"PIK3CA Gene","pik3ca-gene",{"biomarker":335,"count":336,"slug":337},"AT-Rich Interactive Domain-Containing Protein 1A",3,"at-rich-interactive-domain-containing-protein-1a",{"biomarker":339,"count":336,"slug":340},"CLDN6 Gene","cldn6-gene",{"biomarker":342,"count":336,"slug":343},"Folate Receptor Alpha","folate-receptor-alpha",{"biomarker":345,"count":336,"slug":346},"GTPase KRas","gtpase-kras",{"biomarker":348,"count":336,"slug":349},"NF1 Gene","nf1-gene",[351,355,359,363,366,370,373,377,381,384,388,392,396,400,403,407,411,415,418,422,426,430,433,437],{"state":352,"count":353,"slug":354},"Texas",113,"texas",{"state":356,"count":357,"slug":358},"California",93,"california",{"state":360,"count":361,"slug":362},"Florida",88,"florida",{"state":364,"count":361,"slug":365},"New York","new-york",{"state":367,"count":368,"slug":369},"Massachusetts",64,"massachusetts",{"state":371,"count":368,"slug":372},"Ohio","ohio",{"state":374,"count":375,"slug":376},"Virginia",58,"virginia",{"state":378,"count":379,"slug":380},"Michigan",57,"michigan",{"state":382,"count":379,"slug":383},"Pennsylvania","pennsylvania",{"state":385,"count":386,"slug":387},"Tennessee",51,"tennessee",{"state":389,"count":390,"slug":391},"Illinois",50,"illinois",{"state":393,"count":394,"slug":395},"North Carolina",46,"north-carolina",{"state":397,"count":398,"slug":399},"Minnesota",43,"minnesota",{"state":401,"count":398,"slug":402},"New Jersey","new-jersey",{"state":404,"count":405,"slug":406},"Missouri",39,"missouri",{"state":408,"count":409,"slug":410},"Colorado",37,"colorado",{"state":412,"count":413,"slug":414},"Georgia",33,"georgia",{"state":416,"count":413,"slug":417},"Oklahoma","oklahoma",{"state":419,"count":420,"slug":421},"Oregon",32,"oregon",{"state":423,"count":424,"slug":425},"Utah",31,"utah",{"state":427,"count":428,"slug":429},"Arizona",30,"arizona",{"state":431,"count":428,"slug":432},"Washington","washington",{"state":434,"count":435,"slug":436},"Connecticut",29,"connecticut",{"state":438,"count":439,"slug":440},"Wisconsin",27,"wisconsin"]